Free Trial

Ipsen (IPSEY) Stock Price, News & Analysis

+0.09 (+0.27%)
(As of 05/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
345 shs
Average Volume
803 shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
IPSEY stock logo

About Ipsen Stock (OTCMKTS:IPSEY)

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

IPSEY Stock Price History

IPSEY Stock News Headlines

Ipsen Shares Fall After Forecast of Lower Margin
Biotech Stocks Facing FDA Decision In February 2024
See More Headlines
Receive IPSEY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Fiscal Year End

Industry, Sector and Symbol

Diagnostic substances
Current Symbol
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales
$3.58 billion
Cash Flow
$3.52 per share


Free Float
Not Optionable
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. David Loew (Age 57)
    MD, CEO & Director
    Comp: $2.3M
  • Mr. Aymeric Le Chatelier (Age 55)
    Executive VP & CFO
    Comp: $795.09k
  • Dr. Aidan Murphy Ph.D. (Age 58)
    Executive VP and Head of Technical Operations
  • Mr. Craig Marks
    Vice-President of Investor Relations
  • Mr. Francois Garnier (Age 62)
    Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer
  • Ms. Gwenan White
    Executive VP and Head of Communications, Public Affairs & Sustainability
  • Mr. Regis Mulot (Age 58)
    Executive VP & Chief Human Resources Officer
  • Ms. Dominique Bery (Age 53)
    Head of Nordics & Baltics
  • Mr. Bartosz Bednarz D.D.S.
    Executive VP and Head of Global Product & Portfolio Strategy
  • Mr. Philippe Lopes-Fernandes CBO
    Executive VP & Chief Business Officer

IPSEY Stock Analysis - Frequently Asked Questions

Should I buy or sell Ipsen stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IPSEY shares.
View IPSEY analyst ratings
or view top-rated stocks.

How have IPSEY shares performed in 2024?

Ipsen's stock was trading at $29.48 on January 1st, 2024. Since then, IPSEY stock has increased by 12.6% and is now trading at $33.20.
View the best growth stocks for 2024 here

Are investors shorting Ipsen?

Ipsen saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 1,200 shares, an increase of 20.0% from the April 15th total of 1,000 shares. Based on an average daily volume of 1,300 shares, the short-interest ratio is presently 0.9 days.
View Ipsen's Short Interest

How often does Ipsen pay dividends? What is the dividend yield for Ipsen?

Ipsen announced a dividend on Thursday, June 1st. Shareholders of record on Monday, June 5th will be given a dividend of $0.2337 per share on Tuesday, June 27th. This represents a yield of 0.8%. The ex-dividend date of this dividend is Friday, June 2nd. This is a positive change from the stock's previous dividend of $0.23.
Read our dividend analysis for IPSEY

Is Ipsen a good dividend stock?

Ipsen (OTCMKTS:IPSEY) pays an annual dividend of $0.23 per share and currently has a dividend yield of 0.70%.
Read our dividend analysis for IPSEY.

How do I buy shares of Ipsen?

Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IPSEY) was last updated on 5/23/2024 by Staff

From Our Partners